AI Article Synopsis
- The study investigated the level of plasma microRNA-21 (miR-21) in non-small cell lung cancer (NSCLC) patients and its link to chemotherapy response.
- Plasma miR-21 levels were significantly higher in NSCLC patients compared to healthy controls and showed potential as a biomarker with a ROC curve area of 0.729, indicating good specificity and sensitivity.
- The results indicated that lower plasma miR-21 levels were associated with a better response to chemotherapy, suggesting it could be used to predict treatment outcomes in NSCLC patients.
Article Abstract
Objective: To examine plasma microRNA-21 (miR-21) level in patients with non-small cell lung cancer (NSCLC) and its potential correlation with chemotherapeutic response.
Methods: 77 NSCLC patients and 36 age and sex-matched healthy controls were included. Plasma miR-21 concentration was examined using a quantitative real-time reverse transcription polymerase chain reaction assay (qRT-PCR). Potential correlation between plasma mir-21 concentrations with chemotherapeutic responses was analyzed in 35 patients with advanced NSCLC (stages IIIB and IV).
Results: Plasma miR-21 was significantly higher in NSCLC patients relative to the healthy controls (P<0.0001). As a biomarker, plasma mir-21 had a receiver operating characteristic (ROC) curve area of 0.729 with 61.04% sensitivity and 83.33% specificity. Chemotherapeutic response in the 35 patients with advanced NSCLC (stages IIIB and IV) included partial response (PR) (n=11), stable disease and progression disease (SD+PD) (n=24). The overall response rate (CR+PR) was 31.4%. Plasma miR-21 in patients who achieved PR was significantly lower than those who did not respond (SD+PD) (P=0.0487), and comparable to that of the healthy controls (P=0.2744).
Conclusion: Plasma miR-21 is a good biomarker for NSCLC, and could be used to predict responses to chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587548 | PMC |
| http://dx.doi.org/10.1007/s11670-011-0123-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circulating MicroRNAs in Idiopathic Pulmonary Fibrosis: A Narrative Review.
Curr Issues Mol Biol
December 2024
Molecular Biology Laboratory, Department of Research in Pulmonary Fibrosis, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Col. Sección XVI, Mexico City 14080, Mexico.
Idiopathic pulmonary fibrosis (IPF) is a chronic, deathly disease with no recognized effective cure as yet. Furthermore, its diagnosis and differentiation from other diffuse interstitial diseases remain a challenge. Circulating miRNAs have been measured in IPF and have proven to be an adequate option as biomarkers for this disease.
View Article and Find Full Text PDFComparative analysis of extracellular vesicles miRNAs (EV-miRNAs) and cell-free microRNAs (cf-miRNAs) reveals that EV-miRNAs are more promising as diagnostic and prognostic biomarkers for prostate cancer.
Gene
December 2024
Department of General Biology, State University of Londrina, Londrina, Paraná, Brazil. Electronic address:
MicroRNAs can be found intracellularly incorporated into extracellular vesicles (EV-miRNAs) or extracellularly as cell-free miRNAs (cf-miRNAs). This study aimed to compare the diagnostic and prognostic potential of four miRNAs with recognized roles in prostate cancer as cf-miRNAs and EV-miRNAs, obtained from liquid biopsies (LB). Total RNA was isolated from whole plasma and plasma EVs from 15 controls (CTR) and 30 patients (20 with localized prostate cancer (PCa), 10 with metastatic prostate cancer (mPCa)).
View Article and Find Full Text PDFAssociation of plasma microRNAs with COVID-19 severity and outcome.
J Genet Eng Biotechnol
December 2024
Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Objective: As one of the remarkable host responses to SARS-CoV-2 infection, circulating microRNAs (miRNAs) represent important diagnostic and prognostic diseases biomarkers. The study is a step towards highlighting the role of miRNAs in COVID-19 pathogenesis and severity.
Methods: In this case-control study, miRCURY LNA miRNA PCR plasma panel (168 miRNAs) was applied and the expression of the altered miRNAs was then analysed by quantitative real time PCR for 120 COVID-19 patients (30 mild, 30 moderate, 30 severe, and 30 critical) and 30 healthy subjects.
Autocrine small extracellular vesicles induce tubular phenotypic transformation in diabetic nephropathy via miR-21-5p.
Gene
February 2025
Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province 341000, China; The First School of Clinical Medicine, Gannan Medical University, Ganzhou, Jiangxi Province 341000, China. Electronic address:
Background: Diabetic nephropathy (DN) is one of the most common and serious microvascular complications associated with diabetes. DN is the leading contributor to the majority of cases of end-stage renal disease (ESRD). Small extracellular vesicles (sEVs) can transport various genetic materials to recipient cells.
View Article and Find Full Text PDFTumor Suppressor miR-34a: Potential Biomarker of TACE Response in HCC.
Cardiovasc Intervent Radiol
December 2024
Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Jihlavská 340/20, 625 00, Brno, Czechia.
Article Synopsis
- The study investigates the effects of TACE treatment on microRNA levels and VEGF in HCC patients, comparing two types of particles: degradable (DSM) and nondegradable (DEB).
- It included 52 patients, measuring biomarker concentrations at different time points before and after TACE to assess treatment responses at six and twelve months.
- Results showed that while both particle types raised microRNA levels post-TACE, only miR-34a’s immediate increase correlated with better outcomes, suggesting it could be a useful biomarker for predicting patient prognosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!